-
1 Comment
Brooks Laboratories Limited is currently in a long term uptrend where the price is trading 18.7% above its 200 day moving average.
From a valuation standpoint, the stock is 64.5% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.7.
Brooks Laboratories Limited's total revenue rose by 5.2% to $209M since the same quarter in the previous year.
Its net income has increased by 9.0% to $-26M since the same quarter in the previous year.
Finally, its free cash flow fell by 56.5% to $6M since the same quarter in the previous year.
Based on the above factors, Brooks Laboratories Limited gets an overall score of 4/5.
| Exchange | NSE |
|---|---|
| CurrencyCode | INR |
| ISIN | INE650L01011 |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Market Cap | 4B |
|---|---|
| PE Ratio | None |
| Target Price | 53 |
| Beta | 1.47 |
| Dividend Yield | None |
Brooks Laboratories Limited manufactures and sells pharmaceuticals in India and internationally. The company offers liquid and dry powder injection, carbapenem dry powder injectables, tablets, oral suspension, dry syrup, and eye/ear drops. Brooks Laboratories Limited was incorporated in 2002 and is based in Mumbai, India.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for BROOKS.NSE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
